Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
LYR– Positive ENLIGHTEN 2 Phase 3 results announced in June 2025 propel business activities in manufacturing, regulatory strategy and ENLIGHTEN clinical dataset analysis to advance path forward for LYR-210 for treatment of chronic rhinosinusitis (CRS) –
August 12, 2025Clinical
Read more →